Please login to the form below
REGN5458
This page shows the latest REGN5458 news and features for those working in and with pharma, biotech and healthcare.
GSK files anti-BCMA drug for myeloma after second trial win
Other drugs making their way through development include bispecific antibodies from Amgen ( AMG 420), Regeneron (REGN5458) and Bluebird Bio/Bristol-Myers Squibb (CC-92369), as well as ADCs from AstraZeneca (MEDI2228)
Latest news
-
Regeneron reveals first data for bispecific antibody in multiple myeloma
Regeneron has made its first appearance on the BCMA scene, revealing data for its bispecific antibody candidate REGN5458 in multiple myeloma. . ... The much anticipated first results from the first two dose groups in the phase 1/2 trial of REGN5458 were
-
Sanofi and Regeneron re-jig immuno-oncology deal
The two candidates selected as most promising are REGN5458 (aka BCMAxCD3), a BCMA and CD3 targeting bispecific antibody and REGN4018, a MUC16 and CD3 targeting bispecific antibody.
More from news
Approximately 1 fully matching, plus 2 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
-
Account Management
-
Competitive Salary Offered
- FREELANCE Medical Writer, Senior Medical Writer, Principal Medic...
-
Highly Competitive Day Rate, Bonus &Benefits
- Senior Leadership Role – Medical Communications – North West
-
Highly Competitive Salary, Bonus &Benefits
- Senior Content Editor - Biotechnology
-
Salary TBC
- Freelance Account Manager - Creative Healthcare Comms - Immediat...
-
Excellent Day Rate
- Senior Account / Programme Manager - MedComms - Buckinghamshire
-
Highly Competitive Remuneration packages
- Freelance Medical Writer - Creative Healthcare Comms - 2 month t...
-
Excellent Day Rate
-
Principal Medical Writer
-
Varies on experience
- CureVac expands COVID-19 vaccine trial protocol to include variant specification
- Pfizer helps fund biotech venture from former researchers at closed Kent facility
- Bayer’s finerenone scores FDA priority review for chronic kidney disease
- J&J looks ahead at potential flu therapy after approval of its COVID-19 vaccine
- New restrictions for AZ/Oxford COVID-19 vaccine despite EMA endorsement
- Moderna launches COVID-19 vaccine booster study to address new variants
- Live Webinar: Nanobiotechnology, Artificial Intelligence, and Virtual Care
- Opdivo improves survival in oesophageal cancer
- Keytruda shows significant and meaningfully improvement in kidney cancer
- Congress 2020 BC (before COVID-19)
- Shaping the Future of Medicine, Science, and Technology
- Live Webinar: Virtual Trials, Remote Care, & Cross-Border Collaboration: Ethical & Legal Challenges
Latest intelligence
- Virtual congresses: video thrilled the cardio tsar
- Chris Ross explores the key learnings from a year of virtual congresses...
- When Will We Be Back To Normal?
- The definitive question of 2021, whether you’re a homeschooling parent, a homebound professional, a wanderer with nowhere to go… or all three at once....
- How to tell your healthcare story.
- Healthcare research is not a simple story and the people in charge of those moments need to be careful about the story that they tell....
Quick links
Infographics
